SG11202101751XA - 5 to 7 membered heterocyclic amides as jak inhibitors - Google Patents
5 to 7 membered heterocyclic amides as jak inhibitorsInfo
- Publication number
- SG11202101751XA SG11202101751XA SG11202101751XA SG11202101751XA SG11202101751XA SG 11202101751X A SG11202101751X A SG 11202101751XA SG 11202101751X A SG11202101751X A SG 11202101751XA SG 11202101751X A SG11202101751X A SG 11202101751XA SG 11202101751X A SG11202101751X A SG 11202101751XA
- Authority
- SG
- Singapore
- Prior art keywords
- membered heterocyclic
- jak inhibitors
- heterocyclic amides
- amides
- jak
- Prior art date
Links
- -1 7 membered heterocyclic amides Chemical class 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726583P | 2018-09-04 | 2018-09-04 | |
| PCT/US2019/049342 WO2020051139A1 (en) | 2018-09-04 | 2019-09-03 | 5 to 7 membered heterocyclic amides as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101751XA true SG11202101751XA (en) | 2021-03-30 |
Family
ID=68051893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101751XA SG11202101751XA (en) | 2018-09-04 | 2019-09-03 | 5 to 7 membered heterocyclic amides as jak inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10836763B2 (de) |
| EP (1) | EP3837010B1 (de) |
| JP (1) | JP7383696B2 (de) |
| KR (1) | KR20210056380A (de) |
| CN (1) | CN112703037B (de) |
| AR (1) | AR116114A1 (de) |
| AU (1) | AU2019335200A1 (de) |
| BR (1) | BR112021004063A2 (de) |
| CL (1) | CL2021000515A1 (de) |
| CO (1) | CO2021002976A2 (de) |
| EA (1) | EA202190686A1 (de) |
| ES (1) | ES2955717T3 (de) |
| IL (1) | IL281150B2 (de) |
| MX (1) | MX2021002484A (de) |
| PH (1) | PH12021550324A1 (de) |
| SG (1) | SG11202101751XA (de) |
| TW (1) | TWI793365B (de) |
| UA (1) | UA127328C2 (de) |
| WO (1) | WO2020051139A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016004079A1 (en) | 2014-06-30 | 2016-01-07 | Black & Decker Inc. | Battery pack for a cordless power tools |
| EP3371186A1 (de) | 2015-11-03 | 2018-09-12 | Theravance Biopharma R&D IP, LLC | Jak-kinase-inhibitorverbindungen zur behandlung von atemwegserkrankungen |
| AU2018231035B2 (en) | 2017-03-09 | 2021-09-09 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine JAK inhibitors |
| KR20210056382A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 및 이의 중간체를 제조하는 방법 |
| IL281150B2 (en) * | 2018-09-04 | 2024-03-01 | Theravance Biopharma R& D Ip Llc | Heterocyclic amides with 5 to 7 atoms as JAK inhibitors |
| EP3837258B1 (de) | 2018-09-04 | 2024-04-24 | Theravance Biopharma R&D IP, LLC | Dimethylaminoazetidinamide als jak-inhibitoren |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| WO2022081872A1 (en) * | 2020-10-16 | 2022-04-21 | Gb008, Inc. | Janus kinase inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102821607B (zh) | 2009-12-21 | 2014-12-17 | 萨穆梅德有限公司 | 1H-吡唑并[3，4-b]吡啶及其治疗应用 |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| JP6192839B2 (ja) | 2013-12-05 | 2017-09-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド |
| MX2016014878A (es) | 2014-05-14 | 2017-03-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas. |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| EP3371184A1 (de) | 2015-11-03 | 2018-09-12 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin- und 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepin-derivate als janus-kinase-inhibitoren |
| CA3037248A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| EP3371186A1 (de) | 2015-11-03 | 2018-09-12 | Theravance Biopharma R&D IP, LLC | Jak-kinase-inhibitorverbindungen zur behandlung von atemwegserkrankungen |
| CA3030381A1 (en) * | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| AU2018231035B2 (en) | 2017-03-09 | 2021-09-09 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine JAK inhibitors |
| TWI808083B (zh) | 2017-05-01 | 2023-07-11 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶型式 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| IL281150B2 (en) * | 2018-09-04 | 2024-03-01 | Theravance Biopharma R& D Ip Llc | Heterocyclic amides with 5 to 7 atoms as JAK inhibitors |
| EP3837258B1 (de) | 2018-09-04 | 2024-04-24 | Theravance Biopharma R&D IP, LLC | Dimethylaminoazetidinamide als jak-inhibitoren |
| KR20210056382A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 및 이의 중간체를 제조하는 방법 |
| US10968222B2 (en) | 2018-10-29 | 2021-04-06 | Theravance Biopharma R&D Ip, Llc | 2-azabicyclo hexane JAK inhibitor compound |
| CN113563345A (zh) | 2019-02-25 | 2021-10-29 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
| CA3132371A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| CN112279848A (zh) | 2019-07-25 | 2021-01-29 | 四川海思科制药有限公司 | 一种泛JAKs抑制剂及其用途 |
-
2019
- 2019-09-03 IL IL281150A patent/IL281150B2/en unknown
- 2019-09-03 AU AU2019335200A patent/AU2019335200A1/en not_active Abandoned
- 2019-09-03 JP JP2021512242A patent/JP7383696B2/ja active Active
- 2019-09-03 EP EP19773584.8A patent/EP3837010B1/de active Active
- 2019-09-03 EA EA202190686A patent/EA202190686A1/ru unknown
- 2019-09-03 UA UAA202101706A patent/UA127328C2/uk unknown
- 2019-09-03 SG SG11202101751XA patent/SG11202101751XA/en unknown
- 2019-09-03 AR ARP190102519A patent/AR116114A1/es unknown
- 2019-09-03 CN CN201980057601.7A patent/CN112703037B/zh active Active
- 2019-09-03 KR KR1020217009933A patent/KR20210056380A/ko not_active Application Discontinuation
- 2019-09-03 MX MX2021002484A patent/MX2021002484A/es unknown
- 2019-09-03 BR BR112021004063-3A patent/BR112021004063A2/pt unknown
- 2019-09-03 ES ES19773584T patent/ES2955717T3/es active Active
- 2019-09-03 US US16/559,138 patent/US10836763B2/en active Active
- 2019-09-03 TW TW108131710A patent/TWI793365B/zh active
- 2019-09-03 WO PCT/US2019/049342 patent/WO2020051139A1/en active Application Filing
-
2020
- 2020-10-13 US US16/949,067 patent/US11713315B2/en active Active
-
2021
- 2021-02-15 PH PH12021550324A patent/PH12021550324A1/en unknown
- 2021-03-02 CL CL2021000515A patent/CL2021000515A1/es unknown
- 2021-03-04 CO CONC2021/0002976A patent/CO2021002976A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3837010C0 (de) | 2023-07-05 |
| KR20210056380A (ko) | 2021-05-18 |
| JP7383696B2 (ja) | 2023-11-20 |
| US20210024517A1 (en) | 2021-01-28 |
| BR112021004063A2 (pt) | 2021-05-25 |
| EP3837010A1 (de) | 2021-06-23 |
| US10836763B2 (en) | 2020-11-17 |
| US20200071325A1 (en) | 2020-03-05 |
| IL281150B1 (en) | 2023-11-01 |
| CO2021002976A2 (es) | 2021-05-31 |
| JP2021535174A (ja) | 2021-12-16 |
| WO2020051139A1 (en) | 2020-03-12 |
| TW202024075A (zh) | 2020-07-01 |
| EP3837010B1 (de) | 2023-07-05 |
| AU2019335200A1 (en) | 2021-03-11 |
| IL281150B2 (en) | 2024-03-01 |
| US11713315B2 (en) | 2023-08-01 |
| MX2021002484A (es) | 2021-05-12 |
| PH12021550324A1 (en) | 2021-10-04 |
| CN112703037B (zh) | 2023-10-20 |
| CN112703037A (zh) | 2021-04-23 |
| TWI793365B (zh) | 2023-02-21 |
| AR116114A1 (es) | 2021-03-31 |
| IL281150A (en) | 2021-04-29 |
| EA202190686A1 (ru) | 2021-07-23 |
| UA127328C2 (uk) | 2023-07-19 |
| CL2021000515A1 (es) | 2021-07-23 |
| ES2955717T3 (es) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281150A (en) | Heterocyclic amides with 5 to 7 atoms as JAK inhibitors | |
| IL266214A (en) | 5,4,2-trisubstituted 4,2,1-triazolones used as DHODH inhibitors | |
| IL275379A (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as SOS1 inhibitors | |
| SG10202110874TA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| ZA201707176B (en) | Heterocyclic amides as kinase inhibitors | |
| IL268004B (en) | History of tyrosine amide as rho-kinase inhibitors | |
| IL267090A (en) | Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them | |
| TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| IL281146A (en) | Dimethyl amino aztidine amides as JAK inhibitors | |
| IL272016A (en) | Pyrrolidine history and their use as TLR7/8 antagonists | |
| HK1251566A1 (zh) | 作為hdac1/2抑制劑的呱啶衍生物 | |
| IL273657A (en) | Use of p38 inhibitors to reduce expression of dux4 | |
| EP3666770A4 (de) | Neue heterozyklische verbindungen als cdk8/19-inhibitoren | |
| IL269695A (en) | Compounds useful as ALCAT 1 inhibitors | |
| MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| GB201708390D0 (en) | Novel alpha-amino amide derivatives | |
| IL277869A (en) | Substituted propanamides as nuclease inhibitors |